![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Elite Pharmaceuticals, | AMEX:ELI | AMEX | Ordinary Share |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.00 | - |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
October 24, 2007
---------------------------
(Date of Report)
ELITE PHARMACEUTICALS, INC.
-----------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware
|
333-45241
|
22-3542636
|
------------
|
-------------
|
--------------
|
(State or other jurisdiction
of incorporation) |
(Commission
File Number) |
(IRS Employer
Identification No.) |
165 Ludlow Avenue, Northvale, New Jersey 07647
---------------------------------------------------------------
(Address of principal executive offices)
(201) 750-2646
---------------------
(Registrants telephone number, including area code)
Item 8.01 |
Other Events |
The shares of common stock, par value $0.01 per share (the Common Stock), of Elite Pharmaceuticals, Inc. a Delaware corporation (the Registrant), which are listed on the American Stock Exchange, shall be eligible for the Direct Registration System effective as of November 1, 2007. On or after November 1, 2007, the Registrants common stockholders shall have the option to have physical stock certificates evidencing their share ownership or have such shares listed by book-entry on the Direct Registration System.
Stockholders of the Registrant should contact the Registrants transfer agent, Jersey Transfer and Trust Company, if they wish to have the shares listed by book-entry.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Elite Pharmaceuticals, Inc. | ||
Date: October 24, 2007 |
By: |
/s/ Bernard J. Berk |
|
Bernard J. Berk |
|
|
Chief Executive Officer |
1 Year Elite Pharmaceuticals Chart |
1 Month Elite Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions